Median Technologies Shares Climb to €5.17, Targeting €5.50 Resistance
Median Technologies shares have significantly advanced in mid-afternoon trading to €5.17, a gain of 4.34% from the last close at €4.955. The small-cap company from the French Riviera, specializing in AI-assisted medical imaging, is performing in a rising Paris market, with the CAC 40 up by 0.32% during the session. Over the past twelve months, the stock now shows a performance increase of 123.8%.
Median Technologies Challenges €5.50 Resistance and Breaks Above Bollinger Bands
Median Technologies' stock is challenging its technical resistance identified at €5.50 after rebounding from the support level at €4.55. At €5.17, the price has broken above the upper Bollinger Band (upper limit at €5.14), indicating strong buying pressure during the session. The stock is trading above its three moving averages, with a 46.88% gap from the MM200 at €3.52, signaling that the medium-term momentum remains intact. The RSI at 53 remains neutral, allowing for technical leeway despite the Bollinger break. The stock has risen 5.83% over the week and has doubled in value over the year.
Record Order Book of €79.8 Million and FDA Approval Milestone for eyonis
During the announcement of the annual results for 2025 (on April 23, 2026), the company had reduced its operational loss to €16.3 million from €22.5 million a year earlier, and raised its order book to a record level of €79.8 million as of March 31, 2026. Among the opportunities mentioned on this occasion were the anticipated FDA approval for eyonis LCS, its early lung cancer detection solution, and the partnership formed with Tempus to expand access to this technology in the American market. The management also highlighted two risk factors: the decline in Chinese demand and regulatory pressure on approvals. The crossing of the €5.50 mark will be the next technical milestone observable on the stock.
